Two new forms of Actavis's Bupropion are approved in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved 100mg and 200mg tablets of Actavis's extended-release treatment of major depressive disorder Bupropion HCl SR (GlaxoSmithKline's Wellbutrin SR). Actavis has been marketing 150mg tablets of the product in the US since March 2008, and will commence distribution of the two new tablets immediately.